⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14356600 | 0.92 | — | — | |
| SCHEMBL23085669 | 0.81 | — | — | |
| SCHEMBL14356621 | 0.80 | CYP2B6 (0.31) | — | |
| SCHEMBL14356597 | 0.76 | ALDH1A1 (0.35) | — | |
| SCHEMBL23075440 | 0.76 | RAB9A (0.32) | — | |
| SCHEMBL23075936 | 0.74 | ALDH1A1 (0.34) | — | |
| SCHEMBL2285725 | 0.73 | HRH3 (0.36) | — | |
| SCHEMBL3218743 | 0.73 | — | — | |
| SCHEMBL15721208 | 0.73 | RAB9A (0.33) | — | |
| SCHEMBL14356616 | 0.73 | HSD11B1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIGEL PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230057341-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| WO-2023020486-A1 | RIP1 KINASE INHIBITOR COMPOUND AND COMPOSITION AND USE THEREOF | 广州市恒诺康医药科技有限公司 | 2023-02-23 | — | — | WO | disclosed |
| US-11564930-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210069208-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20210070744-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210070743-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210070735-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| WO-2016033243-A9 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-8450315-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-05-28 | — | — | US | disclosed |